AIMM Therapeutics

9 articles about AIMM Therapeutics

• AIMM Therapeutics Presents Preclinical Data on its Four Oncology Therapies at AACR’s Annual Meeting Session on Antibody Technologies

  6/22/2020

  --World-Class Monoclonal Antibody Technology Advances Beyond Infectious Disease to Focus on Oncology Therapeutics Derived from Cancer Survivors-- --Lead Asset AT1412 On Track Towards CTA Filing in Q4 2020-- --Led by New Management Team, Including John Womelsdorf, Ph.D., and Hans van Eenennaam, Ph.D., Co-inventor of Pembrolizumab-- l

• Merus Announces Formation of a Scientific Advisory Board

  8/22/2018

  Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.

• AIMM Therapeutics Signs Exclusive License And Option Agreement With Merck & Co., Kenilworth, NJ, U.S.A. On Preclinical Oncology Targets

  8/2/2017

• AIMM Therapeutics’ Partner MedImmune Starts Clinical Studies With RSV Antibody

  7/2/2014

• AIMM Therapeutics' Pre-Fusion RSV Antibodies Facilitate Improved Approach to Vaccine Development

  11/4/2013

• AIMM Therapeutics Significantly Strengthens Scientific Advisory Board with High Profile Appointments

  6/20/2013

• AIMM Therapeutics in Strategic Partnership With Cosmo Pharmaceuticals S.p.A. to Combine Cosmo's Extended Release Technology & AIMM's High Quality Antibodies to Successfully Combat Gastrointestinal Disease

  12/19/2012

• AIMM Therapeutics Appoints Former Head Novartis Research Institutes Jan de Vries CEO, and John Womelsdorf VP Business Development

  11/8/2012

• AIMM Therapeutics Closes Financing Round With Life Sciences Fund Amsterdam

  6/5/2009